• 1
    Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med. 2002; 347: 417429.
  • 2
    Siminovitch KA. Advances in the molecular dissection of inflammatory bowel disease. Semin. Immunol. 2006; 18: 244253.
  • 3
    Inoue N, Tamura K, Kinouchi Y et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002; 123: 8691.
  • 4
    Yamazaki K, Takazoe M, Tanaka T et al. Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease. J. Hum. Genet. 2004; 49: 664668.
  • 5
    Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients. J. Hum. Genet. 2007; 52: 575583.
  • 6
    Yang SK, Park M, Lim J et al. Contribution of IL23R but not ATG16L1 to Crohn's disease susceptibility in Koreans. Inflamm. Bowel Dis. 2009; 15: 13851390.
  • 7
    Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010; 4: 114.
  • 8
    Cheon JH. Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives. J. Gastroenterol. Hepatol. 2013; 28: 220226.
  • 9
    Yang SK, Yun S, Kim JH et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm. Bowel Dis. 2008; 14: 542549.
  • 10
    Ye BD, Yang SK, Cho YK et al. Clinical features and long-term prognosis of Crohn's disease in Korea. Scand. J. Gastroenterol. 2010; 45: 11781185.
  • 11
    Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract. Res. Clin. Gastroenterol. 2003; 17: 131137.
  • 12
    Lemann M, Mary JY, Duclos B et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 10541061.
  • 13
    D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660667.
  • 14
    Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 2006; 4: 621630.
  • 15
    Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 16171625.
  • 16
    Peyrin-Biroulet L, Khosrotehrani K, Carrat F et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 162128 e1-5.
  • 17
    Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650656.
  • 18
    Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand. J. Gastroenterol. 2008; 43: 948954.
  • 19
    Henriksen M, Jahnsen J, Lygren I, Vatn MH, Moum B. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am. J. Gastroenterol. 2007; 102: 19551963.
    Direct Link:
  • 20
    Solberg IC, Vatn MH, Hoie O et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin. Gastroenterol. Hepatol. 2007; 5: 14301438.
  • 21
    Wolters FL, Russel MG, Sijbrandij J et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 11241130.
  • 22
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 1989; 170: 26; discussion 16–19.
  • 23
    Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 2005; 19 (Suppl. A): 536.
  • 24
    Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am. J. Gastroenterol. 2008; 103: 31673182.
    Direct Link:
  • 25
    Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm. Bowel Dis. 2004; 10: 646651.
  • 26
    Shivananda S, Lennard-Jones J, Logan R et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690697.
  • 27
    Bernstein CN, Wajda A, Svenson LW et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am. J. Gastroenterol. 2006; 101: 15591568.
    Direct Link:
  • 28
    Molinie F, Gower-Rousseau C, Yzet T et al. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988–1999). Gut 2004; 53: 843848.
  • 29
    Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996–2002. Am. J. Gastroenterol. 2008; 103: 19982006.
    Direct Link:
  • 30
    Romberg-Camps MJ, Dagnelie PC, Kester AD et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am. J. Gastroenterol. 2009; 104: 371383.
  • 31
    Vind I, Riis L, Jess T et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am. J. Gastroenterol. 2006; 101: 12741282.
  • 32
    Lapidus A. Crohn's disease in Stockholm County during 1990–2001: an epidemiological update. World J. Gastroenterol. 2006; 12: 7581.
  • 33
    Practice AGAC, Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 2003; 125: 15031507.
  • 34
    Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn's disease over 15 years. Gut 2012; 61: 11401145.
  • 35
    Park SK, Yang SK, Park SH et al. Long-term prognosis of the jejunal involvement of Crohn's disease. J. Clin. Gastroenterol. 2013; 47: 400408.
  • 36
    Jess T, Riis L, Vind I et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm. Bowel Dis. 2007; 13: 481489.
  • 37
    Song XM, Gao X, Li MZ et al. Clinical features and risk factors for primary surgery in 205 patients with Crohn's disease: analysis of a South China cohort. Dis. Colon Rectum 2011; 54: 11471154.
  • 38
    Oriuchi T, Hiwatashi N, Kinouchi Y et al. Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality. J. Gastroenterol. 2003; 38: 942953.
  • 39
    Iida M, Yao T, Okada M. Long-term follow-up study of Crohn's disease in Japan. The Research Committee of Inflammatory Bowel Disease in Japan. J. Gastroenterol. 1995; 30 (Suppl. 8): 1719.
  • 40
    Okada M, Sakurai T, Yao T et al. Clinical course and long-term prognosis of Crohn's disease in Japan. J. Gastroenterol. 1994; 29: 406414.
  • 41
    Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J. Gastroenterol. 2007; 13: 61346139.
  • 42
    Kane SV, Flicker M, Katz-Nelson F. Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission. J. Clin. Gastroenterol. 2005; 39: 3235.
  • 43
    Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am. J. Surg. 2004; 187: 219225.
  • 44
    Morimoto N, Kato J, Kuriyama M et al. Risk factors and indications for first surgery in Crohn's disease patients. Hepatogastroenterology 2007; 54: 20112016.
  • 45
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann. Intern. Med. 1995; 123: 132142.
  • 46
    Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999; 340: 13981405.
  • 47
    Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004; 350: 876885.
  • 48
    Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2009; (4): CD000545.
  • 49
    Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010; 362: 13831395.
  • 50
    Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 15411549.